Targeting mGlu5 for Methamphetamine Use Disorder
Introduction
Psychostimulant abuse places an enormous burden on society, leading to addiction and other devastating consequences. In the United States, overdose deaths linked to psychostimulants with abuse potential, such as methamphetamine, have risen five-fold from 2012 to 2018 (Centers for Disease Control and Prevention, 2020; Kariisa, Scholl, Wilson, Seth, & Hoots, 2019), and further increases are predicted for 2020 (Katz, Goodnough, & Sanger-Katz, 2020). Methamphetamine Use Disorder is characterized by mood disturbances (London et al., 2004), psychosis (Lecomte, Dumais, Dugré, & Potvin, 2018), and impairments in executive function that have been linked to corticostriatal deficits and can interfere with engagement in behavioral therapies (Dean, Groman, Morales, & London, 2013; London, Kohno, Morales, & Ballard, 2015). Yet, decades of research have not yielded an effective medication for the treatment of this disorder. Clinical trials have evaluated pharmacologically diverse medications, such as direct and indirect dopaminergic agonists, antidepressants, cognitive enhancers, and immune modulators (Chan et al., 2019; Paulus & Stewart, 2020; Siefried, Acheson, Lintzeris, & Ezard, 2020). Failures of these trials may be partly attributed to small sample sizes in the face of high dropout rates (Chan et al., 2019; Lee, Jenner, Harney, & Cameron, 2018; Siefried et al., 2020), heterogeneities associated with drug use disorders (Regier, Kampman, & Childress, 2020; Soares & Pereira, 2019), medication nonadherence (Lee et al., 2018; Siefried et al., 2020), and the unrealistic requirement by the U.S. Food and Drug Administration for sustained abstinence as the only valid endpoint in clinical trials for pharmacotherapies for drug use disorders (Kiluk et al., 2016). In addition, it may be helpful to investigate compounds that interact with novel targets. The goal of this review is to encourage research on a class of such compounds, specifically allosteric modulators of the Group-I metabotropic glutamate receptor subtype 5 (mGlu5) in the quest for an effective pharmacotherapy to treat Methamphetamine Use Disorder.
The potential efficacy of mGlu5 allosteric modulators as medications for addiction was highlighted over a decade ago (Markou, 2009; Olive, 2010), and considerable research has promoted interest in the mGlu5 receptor as a target for Cocaine (Mihov & Hasler, 2016), Alcohol (Kumar et al., 2018) and Tobacco Use disorders (Barnes, Sheffler, Semenova, Cosford, & Bespalov, 2018; Chiamulera, Marzo, & Balfour, 2017). As described below, animal studies document a major involvement of mGlu5 in vulnerability to methamphetamine self-administration and its consequences. They indicate substantial potential for mGlu5 allosteric modulators to reduce methamphetamine reward/reinforcement, drug craving and relapse. Here, we review this literature with the goal of expediting its translation into clinical research to develop a medication for Methamphetamine Use Disorder. PubMed and Web of Science were used to search multiple databases for relevant articles, which were then screened for additional literature. Due to space limitations, we do not cover evidence that negative allosteric modulators (NAMs) of mGlu5 protect against methamphetamine-induced neurotoxicity (Battaglia et al., 2002; Cao, Fu, Kumar, & Kumar, 2016; Golembiowska, Konieczny, Wolfarth, & Ossowska, 2003; Miyatake, Narita, Shibasaki, Nakamura, & Suzuki, 2005; Shah, Silverstein, Singh, & Kumar, 2012; Tokunaga et al., 2009).
Section snippets
Group-I metabotropic glutamate receptor subtype 5 (mGlu5)
The mGlu5 receptor belongs to the family of Group-I metabotropic glutamate receptors, which are class C G protein-coupled receptors and part of the seven transmembrane-spanning receptor superfamily (Koehl et al., 2019). These receptors form full-length dimers with their large extracellular N-terminal domains connected by a disulfide bridge and containing the binding sites for glutamate and other orthosteric ligands (Koehl et al., 2019). They also possess a cysteine-rich domain, which propagates
Methamphetamine action and mGlu5 receptor influence on dopamine dynamics
Methamphetamine exerts its psychomotor stimulant effects primarily via acting at plasma membrane monoamine transporters (including the dopamine transporter) and vesicular monoamine transporters, and also by inhibiting monoamine oxidase activity (Sulzer, Sonders, Poulsen, & Galli, 2005). Through these mechanisms, methamphetamine profoundly increases extracellular dopamine in the forebrain (Sulzer et al., 2005). Studies of methamphetamine-induced psychomotor sensitization implicate metabotropic
Psychomotor sensitization to methamphetamine in rodents and mGlu5
Methamphetamine is a psychostimulant that induces motor hyperactivity and repetitive motor patterns, termed stereotypies, in humans (Rusyniak, 2013) and laboratory animals. In rats, the effect is dose-dependent – lower doses increase horizontal movement and higher doses induce stereotypies (Hadamitzky, McCunney, Markou, & Kuczenski, 2012). Repeated methamphetamine exposure sensitizes rats to its psychomotor-activating effects, augmenting drug-elicited motor excitability or inducing stereotypies
Addiction vulnerability and mGlu5: methamphetamine intake and preference in rodents (Table 1)
Inasmuch as high methamphetamine intake or preference in rodents models vulnerability to methamphetamine addiction (Phillips, Mootz, & Reed, 2016; Phillips & Shabani, 2015), a hyperglutamatergic state, involving mGlu5 receptors in the nucleus accumbens, apparently confers such vulnerability (Szumlinski et al., 2017). Mice selectively bred for high methamphetamine intake by drinking (“high-drinking”, MAHDR) exhibit higher methamphetamine-evoked increases in extracellular glutamate and levels of
Animal models of methamphetamine addiction: pharmacological studies targeting mGlu5
Further evidence that mGlu5 receptor signaling is a crucial determinant of methamphetamine preference is provided by place-conditioning studies with the NAMs, MPEP and MTEP. MPEP suppressed the development of methamphetamine-conditioned place preference in mice (Miyatake et al., 2005), and MPEP as well as MTEP inhibited methamphetamine-conditioned place preference in rats (Herrold, Voigt, & Napier, 2013). The observation that an mGlu1 NAM did not alter place preference in rats implicated an mGlu
Methamphetamine-related cognitive deficits and recovery involving mGlu5
Impairments in pivotal cognitive functions (including attention, learning, and memory) are associated with Methamphetamine Use Disorder (Dean et al., 2013; Potvin et al., 2018; Sabrini, Wang, Lin, Ian, & Curley, 2019) and predict poor treatment retention and outcome across substance use disorders (Brorson, Ajo Arnevik, Rand-Hendriksen, & Duckert, 2013). Although there is overlap in performance of individuals with and those without Methamphetamine Use Disorder, the preponderance of evidence
Translational research on glutamate and mGlu5 in substance use disorders
There are no reports on the expression levels or functional status of mGlu5 receptors in the brains of humans who have used methamphetamine chronically, but the question is currently under investigation (https://grantome.com/grant/NIH/R33-DA031441-06). However, lower levels of glutamatergic neurometabolites (glutamate, glutamate + glutamine, N-acetylaspartate + N-acetylaspartylglutamate) have been measured using magnetic resonance spectroscopy in multiple cortical regions of abstinent
Allosteric modulators of mGlu5 as potential medications for Methamphetamine Use Disorder
As reviewed here, mGlu5 NAMs reduce the rewarding/reinforcing properties of methamphetamine across animal models (Table 2). Yet various forms of learning and memory are also altered by mGlu5 NAMs (Perry, Olive, & Lawrence, 2017). These effects include impairment of extinction learning, leading to relapse-like behavior in methamphetamine-preferring mice (Huang et al., 2016). In addition, lack of efficacy and adverse effects, including disturbance in attention and derealization, have been
Conclusions
Animal models demonstrate that mGlu5 receptor signaling is critically involved in vulnerability to and maintenance of methamphetamine-related behaviors and their detrimental sequelae (Table 1, Table 2). Moreover, they show that mGlu5 allosteric modulators block methamphetamine reward/reinforcement, prevent relapse-like behavior and recover methamphetamine-induced cognitive deficits (Table 2). Allosteric modulators of mGlu5 have also produced promising findings in clinical trials for depression
Author ORCID IDs
JP: https://orcid.org/0000-0003-4163-9014. KKS: https://orcid.org/0000-0003-1078-1077. EDL: https://orcid.org/0000-0003-3577-7808
Funding
This work was supported in part by a postdoctoral research grant from the Max Kade Foundation (JP). Other support was provided by the Thomas P. and Katherine K. Chair in Addiction Studies (EDL) and the Marjorie Greene Family Trust (EDL). The funders had no role in the conception of this review, the selection and interpretation of research reports, the preparation of the manuscript, or the decision to submit it for publication.
Conflict of Interest Statement
The authors declare no conflicts of interest.
References (145)
- et al.
Molecular characterization of a novel metabotropic glutamate receptor mGluR5 coupled to inositol phosphate/Ca2+ signal transduction
Journal of Biological Chemistry
(1992) - et al.
Association of long-term nicotine abstinence with normal metabotropic glutamate receptor-5 binding
Biological Psychiatry
(2016) - et al.
Enhancement of dopamine release from the striatum through metabotropic glutamate receptor activation in methamphetamine sensitized rats
Brain Research
(1996) - et al.
Methamphetamine-induced sensitization of dopamine release via a metabotropic glutamate receptor mediated pathway in rat striatal slices
Japanese Journal of Pharmacology
(1997) - et al.
Metabotropic glutamate receptor 5 as a target for the treatment of depression and smoking: Robust preclinical data but inconclusive clinical efficacy
Biological Psychiatry
(2018) - et al.
Chronic methamphetamine self-administration disrupts cortical control of cognition
Neuroscience and Biobehavioral Reviews
(2016) - et al.
Time to relapse following treatment for methamphetamine use: A long-term perspective on patterns and predictors
Drug and Alcohol Dependence
(2014) - et al.
Drop-out from addiction treatment: A systematic review of risk factors
Clinical Psychology Review
(2013) - et al.
Prefrontal glutamate levels differentiate early phase schizophrenia and methamphetamine addiction: A (1)H MRS study at 3 Tesla
Schizophrenia Research
(2014) - et al.
Allosteric modulation of GPCRs: New insights and potential utility for treatment of schizophrenia and other CNS disorders
Neuron
(2017)
Positive allosteric modulation of mGluR5 receptors facilitates extinction of a cocaine contextual memory
Biological Psychiatry
Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats
Neuropharmacology
mGluR5 is necessary for maintenance of methamphetamine-induced associative learning
European Neuropsychopharmacology
12- and 18-month follow-up after residential treatment of methamphetamine dependence: Influence of treatment drop-out and different treatment concepts
Journal of Psychiatric Research
Measures of outcome for stimulant trials: ACTTION recommendations and research agenda
Drug and Alcohol Dependence
Hippocampal metabolites in asthma and their implications for cognitive function
NeuroImage: Clinical
The prevalence of Substance-Induced Psychotic Disorder in methamphetamine misusers: A meta-analysis
Psychiatry Research
Pharmacotherapy for amphetamine dependence: A systematic review
Drug and Alcohol Dependence
Chronic methamphetamine abuse and corticostriatal deficits revealed by neuroimaging
Brain Research
Identification and characterization of a novel splice variant of the metabotropic glutamate receptor 5 gene in human hippocampus and cerebellum
Brain Research. Molecular Brain Research
Imaging glutamate homeostasis in cocaine addiction with the metabotropic glutamate receptor 5 positron emission tomography radiotracer [(11)C]ABP688 and magnetic resonance spectroscopy
Biological Psychiatry
Homer 1a and mGluR5 phosphorylation in reward-sensitive metaplasticity: A hypothesis of neuronal selection and bidirectional synaptic plasticity
Brain Research
Limbic system mGluR5 availability in cocaine dependent subjects: A high-resolution PET [(11)C]ABP688 study
NeuroImage
Cellular localization of mGluR3 and mGluR5 mRNAs in normal and injured rat brain
Brain Research
mGlu5 function in the nucleus accumbens core during the incubation of methamphetamine craving
Neuropharmacology
Cognitive effects of Group I metabotropic glutamate receptor ligands in the context of drug addiction
European Journal of Pharmacology
Astrocytic mGluR5 and the tripartite synapse
Neuroscience
Interoception and drug addiction
Neuropharmacology
mGlu5-mediated signalling in developing astrocyte and the pathogenesis of autism spectrum disorders
Current Opinion in Neurobiology
Behavioral genetic contributions to the study of addiction-related amphetamine effects
Neuroscience and Biobehavioral Reviews
Identification of treatment targets in a genetic mouse model of voluntary methamphetamine drinking
International Review of Neurobiology
Neurobiology of the incubation of drug craving
Trends in Neurosciences
Metabotropic glutamate receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
Transition from moderate to excessive drug intake: Change in hedonic set point
Science
Psychiatric disorders in individuals with methamphetamine dependence: Prevalence and risk factors
Metabolic Brain Disease
Marked global reduction in mGluR5 receptor binding in smokers and ex-smokers determined by [11C]ABP688 positron emission tomography
Proceedings of the National Academy of Sciences of the United States of America
Metabotropic glutamate receptor 5 binding in male patients with Alcohol Use Disorder
Translational Psychiatry
Imbalances in prefrontal cortex CC-Homer1 versus CC-Homer2 expression promote cocaine preference
Journal of Neuroscience
Selective blockade of mGlu5 metabotropic glutamate receptors is protective against methamphetamine neurotoxicity
Journal of Neuroscience
Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials
Science Translational Medicine
A pilot open label, single dose trial of fenobam in adults with fragile X syndrome
Journal of Medical Genetics
Transgenic analyses of Homer2 function within nucleus accumbens subregions in the regulation of methamphetamine reward and reinforcement in mice
Frontiers in Psychiatry
Homer1 scaffold proteins govern Ca2+ dynamics in normal and reactive astrocytes
Cerebral Cortex
Methamphetamine potentiates HIV-1 gp120-mediated autophagy via Beclin-1 and Atg5/7 as a pro-survival response in astrocytes
Cell Death & Disease
The metabotropic glutamate receptor 5 negative allosteric modulator fenobam: Pharmacokinetics, side effects, and analgesic effects in healthy human subjects
Pain
Recovery of decreased metabotropic glutamate receptor 5 availability in abstinent alcohol-dependent patients
Journal of Nuclear Medicine
National drug overdose deaths involving psychostimulants with abuse potential (including methamphetamine), by opioid involvement, number among all ages, 1999–2018
Pharmacotherapy for Methamphetamine/Amphetamine Use Disorder - A systematic review and meta-analysis
Addiction
The metabotropic glutamate 5 receptor modulates extinction and reinstatement of methamphetamine-seeking in mice
PLoS One
Metabotropic glutamate receptor 5 as a potential target for smoking cessation
Psychopharmacology
Cited by (7)
The metabotropic glutamate receptor 5 as a biomarker for psychiatric disorders
2023, International Review of NeurobiologyCitation Excerpt :However, rates of overall use and problematic use are substantially higher for alcohol, nicotine, and cannabis than they are for cocaine and methamphetamine (listed in order of highest to lowest rates of use in the United States among people age 12 and older in 2020) (Samhsa, 2021). Furthermore, mGlu5 action and the potential of mGlu5 modulation as a treatment within the context of cocaine (Hadizadeh et al., 2022; Niedzielska-Andres et al., 2021) and methamphetamine (Petzold, Szumlinski, & London, 2021) use have recently been reviewed. Nicotine is among the most widely consumed psychoactive drugs in the world (Anderson, 2006; Cornelius, Wang, Jamal, Loretan, & Neff, 2020).
Clinical investigations of compounds targeting metabotropic glutamate receptors
2022, Pharmacology Biochemistry and BehaviorReinforcement learning detuned in addiction: integrative and translational approaches
2022, Trends in NeurosciencesCitation Excerpt :However, recent studies in alcohol-dependent individuals, and in rats with an extended history of cocaine self-administration have observed greater prefrontal mGlu5 receptor availability compared with controls [21,78,79] and found that the degree of increase in mGlu5 receptor availability is related to the quantity of drug use [21]. Moreover, in rats, cocaine-induced changes in prefrontal mGlu5, but not midbrain D3, receptor availability are related to drug-induced impairments in negative outcome updating and relapse-like behaviors [21], suggesting that dysregulation of the mGlu5 receptors is involved in the decision-making problems and high rates of recidivism observed in substance-dependent individuals [80]. These data support an overarching scheme wherein the neurochemical abnormalities observed in substance-dependent individuals are associated with select reinforcement-learning mechanisms that underlie different stages of addiction pathology.
Substance abuse and neurotransmission
2022, Advances in PharmacologyCitation Excerpt :Moreover, the metabotropic GLU receptor, mGlu5, mediates METH effects on DA dynamics and behavior. Negative allosteric modulators of mGlu5 attenuated METH effects on striatal DA and METH-conditioned place preference (Petzold, Szumlinski, & London, 2021). On the other hand, METH also increases NE levels via inhibition of both NET and presynaptic α-adrenergic receptors (α-ARs) (Ferrucci et al., 2019).
Homer signaling pathways as effective therapeutic targets for ischemic and traumatic brain injuries and retinal lesions
2022, Neural Regeneration ResearchIntegrated Care for Pregnant Women and Parents With Methamphetamine-Related Mental Disorders
2021, Frontiers in Psychiatry